Drug Database
RE

recombinant human insulin (insulin, HEC Pharm)

✓ Approved

HEC Pharm · INSR · Recombinant Proteins

What is recombinant human insulin?

recombinant human insulin is a recombinant proteins developed by HEC Pharm. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

Brand Namesinsulin, HEC Pharm
CompanyHEC Pharm
Drug ClassRecombinant Proteins
Molecular TargetINSR
RouteInjectable (Others), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, HEC Pharm

Mechanism of Action

Molecular Targets

recombinant human insulin acts on 1 molecular target:

INSRinsulin receptor (CD220, HHF5)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

recombinant human insulin is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Metabolism and nutrition disordersType 1 diabetes mellitus✓ Approved
Metabolism and nutrition disordersType 2 diabetes mellitus✓ Approved

Related Research Articles

PubMedPediatric endocrinology, diabetes, and metabolism2026-10-22

Efficacy of recombinant growth hormone therapy in children born small for gestational age (SGA): a retrospective analysis.

Pałysa Aleksandra A, Kopiec-Burdecka Monika M, Pyrżak Beata B

Children born small for gestational age (SGA) present with a birth weight or length below -2 standard deviations (SD) relative to population norms for gestational age and sex. In Poland, such patients are eligible for recombinant human growth hormone (rhGH) therapy reimbursed by the National Health Fund. To retrospectively assess the effectiveness of rhGH therapy in children diagnosed with SGA based on clinical data from 39 patients treated with rhGH between 2016 and 2025. Anthropometric data were analysed at therapy initiation and completion. Treatment duration and changes in height and weight SD score (SDS) were evaluated. The influence of age at treatment initiation and sex on therapy outcomes was also assessed. The mean treatment duration was 3 years and 9 months. The average annual height gain was 6.9 cm/year and weight gain 5.3 kg/year. Boys showed a significantly higher annual height gain than girls (p = 0.013), while weight gain differences were not significant (p = 0.08). An improvement in both height and weight SDS was observed across all age groups, with the most pronounced benefits among children who began therapy before the age of 10 years. The most frequent reason for treatment discontinuation was reduced growth velocity. rhGH therapy in children born SGA is effective and safe, resulting in an improvement in growth parameters. The best outcomes are achieved when treatment is initiated in early childhood. The therapy is safe when accompanied by appropriate metabolic monitoring.

PMID 42902698
Read full article →
PubMedPediatric endocrinology, diabetes, and metabolism2026-10-22

Metabolic outcomes and insulin therapy modifications during Ramadan fasting in children with type 1 diabetes mellitus in low-resource settings.

Puspitasari Ajeng Dias AD, Perwitasari Rayi Kurnia RK, Hisbiyah Yuni Y, Abu-Libdeh Abdulsalam I AI et al.

Young Muslims with type 1 diabetes mellitus (T1DM) face serious metabolic challenges during Ramadan fasting, particularly hypoglycemia, hyperglycemia, dehydration, and diabetic ketoacidosis (DKA) risks. Data from low-resource settings (LRS) with limited advanced monitoring tools are insufficient despite established guidelines. This study planned to evaluate metabolic outcomes and insulin modifications among children and adolescents with T1DM during Ramadan fasting in Surabaya, Indonesia. Our cross-sectional study recruited 25 individuals with T1DM aged 7 to 18 years who fasted for at least two weeks during Ramadan 2025. Data were collected via questionnaires and glucose logbooks. Fasting blood glucose (FBG) was measured before, during, and after Ramadan. We also evaluated insulin total daily dose (TDD) and acute complication incidences. The respondents were predominantly female (80%) with a mean HbA1c of 10.22 ±2.29%. During Ramadan, the mean TDD decreased from 0.84 ±0.18 to 0.80 ±0.19 U/kg/day, reflecting a 6.79% reduction in basal insulin. Mean FBG levels remained stable across the pre-, during-, and post-Ramadan periods (202.89, 193.44, and 206.90 mg/dl, respectively; p > 0.05). Clinical safety improved during fasting, with hypoglycemia rates decreasing from 28% to 12% and zero cases of DKA compared to a 16% pre-Ramadan history. Ramadan fasting is safe and feasible for young Muslims with T1DM in LRS when supported by structured pre-fasting education and individualized insulin modifications. These results emphasize that metabolic stability can be achieved through rigorous monitoring and clinical supervision even in the absence of advanced diabetes technologies.

PMID 42902702
Read full article →
PubMedFrontiers in oncology2026-10-22

Case Report: Solitary fibrous tumor of the pelvis associated with Doege-Potter syndrome.

Tan Xiaolong X, Dong Weikai W, Chang Wenli W, Chen Xi X

Solitary fibrous tumor (SFT) is an uncommon mesenchymal spindle cell neoplasm (incidence ~1.4 per million). Although most SFT occur in the thoracic cavity, they can also arise in the retroperitoneum, pelvis, head, and neck. While the majority exhibit benign behavior, approximately 5% are associated with paraneoplastic syndromes, most notably Doege-Potter syndrome (DPS). DPS is characterized by non-islet cell tumor hypoglycemia (NICTH) resulting from tumor hypersecretion of high-molecular-weight insulin-like growth factor 2 (IGF2), which saturates insulin and IGF receptors causing refractory, life-threatening hypoglycemia. Due to nonspecific presentation and low incidence, DPS secondary to pelvic SFT is frequently misdiagnosed, underscoring the need for heightened clinical awareness. A 56-year-old man presented to the neurology department with acute loss of consciousness, aphasia, and urinary incontinence. He had a 3-year history of hypertension but no diabetes mellitus. Initial laboratory tests showed a blood glucose of 4.76 mmol/L; however, during hospitalization, he developed recurrent severe hypoglycemia, with a nadir glucose of 1.6 mmol/L. Further biochemical evaluation during fasting hypoglycemia revealed undetectable insulin (<0.2 mIU/L) and low C-peptide (0.14 ng/mL). Contrast-enhanced abdominopelvic CT demonstrated a 17.8 cm heterogeneously enhancing pelvic mass causing bladder compression and left ureteral displacement. The patient declined preoperative biopsy. Preoperative euglycemia was maintained with continuous intravenous dextrose infusion, and open en bloc surgical resection was performed. Histopathology and immunohistochemistry (positive for STAT6, CD34, and CD99; Ki-67 8%) confirmed an atypical solitary fibrous tumor. Postoperatively, hypoglycemic symptoms resolved completely, and the patient was discharged on postoperative day 6 without further hypoglycemic episodes. Pelvic SFT with DPS frequently presents with recurrent hypoglycemia or altered consciousness rather than local compressive symptoms. Early recognition of non-islet cell tumor hypoglycemia (NICTH) and prompt cross-sectional imaging are essential for accurate diagnosis. Complete surgical resection is definitive and results in full resolution of hypoglycemia. Given the unpredictable biological behavior of SFT, long-term follow-up is essential. Heightened clinical awareness may improve diagnostic accuracy and patient outcomes.

PMID 42903137
Read full article →
PubMedFrontiers in nutrition2026-10-22

Time-restricted feeding during the inactive phase vs. ad libitum feeding: diet-dependent effects on weight and metabolic markers in male Wistar rats.

Hajhamidiasl Ladan L, Baş Murat M, Yilmaz Ozgur O, Ozer Samed S et al.

In recent years, intermittent fasting has become a popular method for preventing and treating obesity and chronic diseases. This study explored the metabolic and inflammatory effects of inactive-phase (Day) time-restricted feeding (TRF) vs. ad libitum feeding (Ad) in rats under high-fat (HF) and standard (S) diet for 8 weeks. Four groups (TRF + HF, TRF + S, Ad + S, Ad + HF; n = 7 each) were monitored for temporal changes in key biomarkers, including TNF-α, IL-6, LPS, insulin, glucose, and lipid profiles, and body weight. Baseline-adjusted two-way ANCOVA was used to evaluate the main effects of Diet and Feeding pattern and their interaction, with complementary multivariate analyses performed as sensitivity analyses. Body weight was significantly associated with both Diet and Feeding pattern after baseline adjustment, with the greatest observed weight gain in Ad + HF and the smallest in TRF + S. TNF-α showed a significant Diet × Feeding interaction, characterized by marked reductions in both TRF groups and little change in Ad + HF. Lipid metabolism exhibited distinct interactions between diet type and feeding regimens. Total cholesterol levels increased in both ad libitum-fed groups, whereas a reduction was observed in the TRF + S group. Triglyceride responses also showed pronounced treatment effects, with the TRF + HF group demonstrating the greatest decrease over the intervention period. IL-6, LPS, insulin, glucose, and LDL-C did not display significant group × time interactions. Overall, inactive-phase time-restricted feeding was associated with lower weight gain, favorable changes in selected lipid parameters, and a reduction in TNF-α. No significant Diet × Feeding interactions were observed for IL-6 or LPS, indicating that the inflammatory findings were specific to TNF-α rather than reflective of a generalized anti-inflammatory effect. However, because food intake was not quantitatively measured, these differences cannot be attributed to meal timing independently of possible differences in total energy intake.

PMID 42903068
Read full article →
PubMedPediatric endocrinology, diabetes, and metabolism2026-10-22

Refractory hypoparathyroidism in paediatric autoimmune polyglandular syndrome type 1: successful long-term use of teriparatide.

Perez Carolina C, Adarme Nicolas N, Hernandez Catalina C, Sarmiento Maria Paula MP

Autoimmune polyglandular syndrome type 1 (APS-1) is a rare monogenic disorder caused by pathogenic variants in the autoimmune regulator (AIRE) gene. It typically manifests in childhood with at least two features of the classic triad: chronic mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency. We present the case of an 11-year-old girl from a consanguineous family, with severe hypocalcaemia and chronic oral candidiasis. Despite high-dose calcium and calcitriol therapy, she experienced recurrent symptomatic hypocalcaemia requiring multiple hospitalisations. Genetic testing confirmed homozygosity for the pathogenic AIRE variant c.967_979del, establishing the diagnosis of APS-1. Due to poor biochemical control, teriparatide (parathyroid hormone, PTH [1-34]) was initiated at 20 g twice daily, leading to rapid improvement in calcium-phosphate homeostasis, a 75% reduction in oral calcium requirements, and no further hospitalisations over a two-year period. The therapy was well tolerated with no adverse events. This is the first paediatric case reported in Colombia using recombinant PTH (1-34) for APS-1-related hypoparathyroidism, supporting its therapeutic role in refractory cases.

PMID 42902706
Read full article →
PubMedChemistry & biodiversity2026-10-22

Pentahydroxyflavone and Metformin Mitigate Diabetes-Induced Hepatic Dysfunction in Gamma-Irradiated Rats Through the AMPK-SREBP-1c-SCD1 Pathway.

Gaber Hanaa F B HFB, Moawed Fatma S M FSM, Mahfouz Mohamed K MK, Ahmed Esraa S A ESA et al.

Diabetes mellitus (DM) is a common complication among cancer patients, potentially worsening the adverse effects of radiation therapy. This study aimed to evaluate whether pentahydroxy flavone (PHF) and Metformin (MET) could mitigate liver damage associated with streptozotocin (STZ)-induced diabetes in rats exposed to gamma irradiation (IR). Diabetes was induced in rats by a single dose of STZ (35 mg/kg) and exposure to a cumulative IR dose (4 Gy). Over one month, each treatment group received either PHF (50 mg/kg) or MET (200 mg/kg). Combined treatment with PHF and MET improved lipid profiles, reduced insulin resistance, coupled with diminishing hepatic inflammation (NLRC4) and oxidative stress. Furthermore, co-administration of PHF and MET modulated the AMPK/ SREBP1c/ SCD1-related signaling, ameliorating hepatic steatosis and fibrosis. These findings suggest that PHF combined with MET's could serve as an adjuvant therapy alongside MET to protect against liver damage caused by diabetes and gamma radiation.

PMID 42902859
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about recombinant human insulin